ARK Genomic Ownership
| ARKG Etf | USD 23.32 0.46 2.01% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
ARK |
ARK Etf Ownership Analysis
ARK Genomic is is formed as Regulated Investment Company in the United States. ETF is managed and operated by The Bank of NewYork Mellon Corporation. The fund has 35 constituents with avarage daily trading value of 3.7 M. The fund charges 0.75 percent management fee with a total expences of 0.75 percent of total asset. The fund holds 99.63% of assets under management (AUM) in equities. ARK Genomic Revolution last dividend was 1.054 per share. The fund is an actively-managed exchange-traded fund that will invest under normal circumstances primarily in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the funds investment theme of the genomics revolution . Ark Genomic is traded on BATS Exchange in the United States. For more info on ARK Genomic Revolution please contact the company at NA.Sector Exposure (%)
Investors will always prefer to have their portfolios divercified against different sectors. The broad sector allocation increases the possibility of making a profit or at least avoiding a loss. However, this may also reduce the expected return on ARK Etf. Generally, it depends on diversification level and type but usually, the broader the sector allocation, the less risk can be expected from holding ARK Genomic , and the less return is expected.
Investment Allocations (%)
Top Etf Constituents
| GILD | Gilead Sciences | Stock | |
| ILMN | Illumina | Stock | |
| BMY | Bristol Myers Squibb | Stock | |
| NVS | Novartis AG ADR | Stock | |
| TWST | Twist Bioscience Corp | Stock | |
| NTLA | Intellia Therapeutics | Stock | |
| ARCT | Arcturus Therapeutics Holdings | Stock | |
| PACB | Pacific Biosciences of | Stock | |
| EXAS | EXACT Sciences | Stock | |
| INO | Inovio Pharmaceuticals | Stock | |
| RHHBY | Roche Holding Ltd | OTC Stock | |
| CGEN | Compugen | Stock | |
| TAK | Takeda Pharmaceutical Co | Stock | |
| IONS | Ionis Pharmaceuticals | Stock | |
| MCRB | Seres Therapeutics | Stock | |
| BIIB | Biogen Inc | Stock | |
| IOVA | Iovance Biotherapeutics | Stock | |
| BLUE | Bluebird bio | Stock | |
| FATE | Fate Therapeutics | Stock | |
| VRTX | Vertex Pharmaceuticals | Stock | |
| REGN | Regeneron Pharmaceuticals | Stock | |
| CDNA | Caredx Inc | Stock | |
| CRSP | Crispr Therapeutics AG | Stock | |
| VCYT | Veracyte | Stock | |
| EDIT | Editas Medicine | Stock |
Institutional Etf Holders for ARK Genomic
| ADOCX | Alger Dynamic Opportunities | Mutual Fund | |
| SPEDX | Alger Dynamic Opportunities | Mutual Fund | |
| TMAT | Main Thematic Innovation | Etf | |
| JAVAX | James Aggressive Allocation | Mutual Fund |
ARK Genomic Outstanding Bonds
ARK Genomic issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ARK Genomic Revolution uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ARK bonds can be classified according to their maturity, which is the date when ARK Genomic Revolution has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| APTV 415 01 MAY 52 Corp BondUS00217GAC78 | View | |
| APTV 325 01 MAR 32 Corp BondUS00217GAB95 | View | |
| ASBBNK 1625 22 OCT 26 Corp BondUS00216LAD55 | View | |
| ASBBNK 5398 29 NOV 27 Corp BondUS00216LAF04 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Currently Active Assets on Macroaxis
When determining whether ARK Genomic Revolution is a strong investment it is important to analyze ARK Genomic's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ARK Genomic's future performance. For an informed investment choice regarding ARK Etf, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ARK Genomic Revolution. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in industry. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
The market value of ARK Genomic Revolution is measured differently than its book value, which is the value of ARK that is recorded on the company's balance sheet. Investors also form their own opinion of ARK Genomic's value that differs from its market value or its book value, called intrinsic value, which is ARK Genomic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ARK Genomic's market value can be influenced by many factors that don't directly affect ARK Genomic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ARK Genomic's value and its price as these two are different measures arrived at by different means. Investors typically determine if ARK Genomic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ARK Genomic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.